$MSTX Up to date company activities and other important information about $MSTX
$MSTX
DD Notes ~ http://www.ddnotesmaker.com/MSTX
##### recent news/filings ~ source: finance.yahoo.com
Tue, 24 Jun 2014 14:19:22 GMT ~ Mast Therapeutics' MST-188 Would Fit Well In Merck's Drug Development Pipeline
read full: http://seekingalpha.com/article/2283763-mast-...urce=yahoo
*********************************************************
Fri, 20 Jun 2014 20:31:40 GMT ~ MAST THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vot
read full: http://biz.yahoo.com/e/140620/mstx8-k.html
*********************************************************
Thu, 19 Jun 2014 20:15:00 GMT ~ Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors
- SAN DIEGO, June 19, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development. "We are delighted to welcome Howard to the Board," stated Jack Lief, Chair of Mast's Board of Directors. "His medical training and extensive clinical development and regulatory affairs experience, particularly with cardiovascular agents, is highly relevant to Mast's development programs and will enrich our expertise. We look forward to benefitting from his contributions and insights." Dr. Dittrich currently serves as Chief Medical Officer of Sorbent Therapeutics, a privately-held biopharmaceutical company developing therapies for cardiovascular and renal diseases, a position he has held since February 2012. Previously, from June 2003 until it was acquired by Merck & Co., Inc. in September 2007, Dr. Dittrich served as Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs of NovaCardia, Inc., a clinical-stage pharmaceutical company focused on cardiovascular diseases, and, from September 2007 to June 2011, he co-founded and served as Chief Medical Officer of Sequel Pharmaceuticals, Inc., a privately-held pharmaceutical company spun out from NovaCardia following its acquisition by Merck. Prior to NovaCardia, from 1996 to 2002, Dr. Dittrich held executive positions overseeing clinical development and regulatory affairs at Molecular Biosystems, Inc. and Alliance Pharmaceutical Corp., during which time he was instrumental in gaining U.S. Food and Drug Administration approval of two cardiovascular imaging agents. From 1984 to 1996, he was a full-time faculty member of the Department of Medicine at the University of California, San Diego (UCSD) and, from 1996 to 2011, he served part-time as Clinical Professor of Medicine at UCSD. Dr. Dittrich holds a B.S. d...
read full: http://finance.yahoo.com/news/mast-announces-...00262.html
*********************************************************
Mon, 16 Jun 2014 12:04:21 GMT ~ Mast Therapeutics initiates sub-study within Phase 3 EPIC trial
read full: http://www.theflyonthewall.com/permalinks/ent...EPIC-trial
*********************************************************
Mon, 16 Jun 2014 12:00:00 GMT ~ Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
- SAN DIEGO, June 16, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device. MST-188 has been shown to reduce viscosity and adhesive frictional forces in blood and improve microvascular blood flow. Improvements in the flow of oxygen-carrying blood to tissues and organs can be expected to improve tissue oxygenation, shorten the duration of vaso-occlusive crisis, and limit tissue damage and end-organ dysfunction and failure. Brian M. Culley, Chief Executive Officer, said: "Organ failure, which is the leading cause of premature death in adults with sickle cell disease, is thought to be the consequence of a lifetime of repeated vaso-occlusive events and the resulting ischemia. We believe that measuring effects on microvascular blood flow and tissue oxygenation during vaso-occlusive crisis will be useful to understanding MST-188's potential to improve long-term outcomes for sickle cell patients where multi-decade, survival trials are impractical. MST-188 has already demonstrated an ability to improve microvascular blood flow. Now, this sub-study will demonstrate whether MST-188 also improves tissue oxygenation. Together, these data will provide insight into the potential for MST-188 to reduce end-organ failure and associated premature death in individuals with sickle cell disease."
read full: http://finance.yahoo.com/news/mast-therapeuti...00240.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=MSTX&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=MSTX&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/MSTX/company-info
Ticker: $MSTX
OTC Market Place: Not Available
CIK code: 0001160308
Company name: Mast Therapeutics, Inc.
Company website: http://www.masttherapeutics.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/MSTX/filings
Latest financials: http://www.otcmarkets.com/stock/MSTX/financials
Latest news: http://www.otcmarkets.com/stock/MSTX/news - http://finance.yahoo.com/q/h?s=MSTX+Headlines
Major holdings: http://data.cnbc.com/quotes/MSTX/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=MSTX+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/MSTX.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=MSTX
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Mast+Therapeutics%...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...ics%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.masttherapeutics.com
Alexa: http://www.alexa.com/siteinfo/http://www.mast...utics.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.masttherapeutics.com
Short Sales: http://www.otcmarkets.com/stock/MSTX/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/MSTX/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/MSTX/research
Historical Prices: http://finance.yahoo.com/q/hp?s=MSTX+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=MSTX+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=MSTX+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=MSTX+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=MSTX+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=MSTX+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=MSTX
Balance Sheet: http://finance.yahoo.com/q/bs?s=MSTX
Cash Flow: http://finance.yahoo.com/q/cf?s=MSTX+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/MSTX
Bloomberg: http://www.bloomberg.com/quote/MSTX:US
Morningstar: http://quotes.morningstar.com/stock/s?t=MSTX
Bussinessweek: http://investing.businessweek.com/research/st...icker=MSTX
Barchart: http://www.barchart.com/quotes/stocks/MSTX
OTC Short Report: http://otcshortreport.com/index.php?index=MSTX
Investopedia: http://www.investopedia.com/markets/stocks/MSTX/?wa=0
http://www.pennystocktweets.com/stocks/profile/MSTX
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/MSTX
$MSTX
DD Notes ~ http://www.ddnotesmaker.com/MSTX
##### recent news/filings ~ source: finance.yahoo.com
Tue, 24 Jun 2014 14:19:22 GMT ~ Mast Therapeutics' MST-188 Would Fit Well In Merck's Drug Development Pipeline
read full: http://seekingalpha.com/article/2283763-mast-...urce=yahoo
*********************************************************
Fri, 20 Jun 2014 20:31:40 GMT ~ MAST THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vot
read full: http://biz.yahoo.com/e/140620/mstx8-k.html
*********************************************************
Thu, 19 Jun 2014 20:15:00 GMT ~ Mast Announces Appointment Of Howard C. Dittrich M.D. To Board of Directors
- SAN DIEGO, June 19, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that Howard C. Dittrich, M.D., F.A.C.C., has joined its Board of Directors. Dr. Dittrich, a cardiologist by training, has more than 20 years of experience in cardiac therapeutic research and clinical development. "We are delighted to welcome Howard to the Board," stated Jack Lief, Chair of Mast's Board of Directors. "His medical training and extensive clinical development and regulatory affairs experience, particularly with cardiovascular agents, is highly relevant to Mast's development programs and will enrich our expertise. We look forward to benefitting from his contributions and insights." Dr. Dittrich currently serves as Chief Medical Officer of Sorbent Therapeutics, a privately-held biopharmaceutical company developing therapies for cardiovascular and renal diseases, a position he has held since February 2012. Previously, from June 2003 until it was acquired by Merck & Co., Inc. in September 2007, Dr. Dittrich served as Chief Medical Officer and Senior Vice President of Clinical and Regulatory Affairs of NovaCardia, Inc., a clinical-stage pharmaceutical company focused on cardiovascular diseases, and, from September 2007 to June 2011, he co-founded and served as Chief Medical Officer of Sequel Pharmaceuticals, Inc., a privately-held pharmaceutical company spun out from NovaCardia following its acquisition by Merck. Prior to NovaCardia, from 1996 to 2002, Dr. Dittrich held executive positions overseeing clinical development and regulatory affairs at Molecular Biosystems, Inc. and Alliance Pharmaceutical Corp., during which time he was instrumental in gaining U.S. Food and Drug Administration approval of two cardiovascular imaging agents. From 1984 to 1996, he was a full-time faculty member of the Department of Medicine at the University of California, San Diego (UCSD) and, from 1996 to 2011, he served part-time as Clinical Professor of Medicine at UCSD. Dr. Dittrich holds a B.S. d...
read full: http://finance.yahoo.com/news/mast-announces-...00262.html
*********************************************************
Mon, 16 Jun 2014 12:04:21 GMT ~ Mast Therapeutics initiates sub-study within Phase 3 EPIC trial
read full: http://www.theflyonthewall.com/permalinks/ent...EPIC-trial
*********************************************************
Mon, 16 Jun 2014 12:00:00 GMT ~ Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial
- SAN DIEGO, June 16, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX) today announced that, in line with prior guidance, it has initiated patient enrollment in a sub-study within EPIC, its pivotal phase 3 study of MST-188 in sickle cell disease, to investigate and quantify the effect of MST-188 on tissue oxygenation, which will be measured utilizing a non-invasive, FDA-approved device. MST-188 has been shown to reduce viscosity and adhesive frictional forces in blood and improve microvascular blood flow. Improvements in the flow of oxygen-carrying blood to tissues and organs can be expected to improve tissue oxygenation, shorten the duration of vaso-occlusive crisis, and limit tissue damage and end-organ dysfunction and failure. Brian M. Culley, Chief Executive Officer, said: "Organ failure, which is the leading cause of premature death in adults with sickle cell disease, is thought to be the consequence of a lifetime of repeated vaso-occlusive events and the resulting ischemia. We believe that measuring effects on microvascular blood flow and tissue oxygenation during vaso-occlusive crisis will be useful to understanding MST-188's potential to improve long-term outcomes for sickle cell patients where multi-decade, survival trials are impractical. MST-188 has already demonstrated an ability to improve microvascular blood flow. Now, this sub-study will demonstrate whether MST-188 also improves tissue oxygenation. Together, these data will provide insight into the potential for MST-188 to reduce end-organ failure and associated premature death in individuals with sickle cell disease."
read full: http://finance.yahoo.com/news/mast-therapeuti...00240.html
*********************************************************
##### chart ~ source: stockcharts.com
stockcharts.com/c-sc/sc?s=MSTX&p=D&b=5&g=0&id=p95448242713
##### chart ~ source: eoddata.com
http://chart.eoddata.com/?e=OTCBB&s=MSTX&...D&b=BB
##### company info ~ source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/MSTX/company-info
Ticker: $MSTX
OTC Market Place: Not Available
CIK code: 0001160308
Company name: Mast Therapeutics, Inc.
Company website: http://www.masttherapeutics.com
Incorporated In: DE, USA
##### extra dd links
Edgar filings: http://www.sec.gov/cgi-bin/browse-edgar?actio...p;count=40
Latest filings: http://www.otcmarkets.com/stock/MSTX/filings
Latest financials: http://www.otcmarkets.com/stock/MSTX/financials
Latest news: http://www.otcmarkets.com/stock/MSTX/news - http://finance.yahoo.com/q/h?s=MSTX+Headlines
Major holdings: http://data.cnbc.com/quotes/MSTX/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=MSTX+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/MSTX.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=MSTX
RegSho: http://www.regsho.com/tools/symbol_stats.php?...rch=search
DTCC: http://search2.dtcc.com/?q=Mast+Therapeutics%...ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&am...ics%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results...=0&y=0
WHOIS: http://whois.domaintools.com/http://www.masttherapeutics.com
Alexa: http://www.alexa.com/siteinfo/http://www.mast...utics.com#
Corporate website internet archive: http://web.archive.org/web/*/http://www.masttherapeutics.com
Short Sales: http://www.otcmarkets.com/stock/MSTX/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/MSTX/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/MSTX/research
Historical Prices: http://finance.yahoo.com/q/hp?s=MSTX+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=MSTX+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=MSTX+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=MSTX+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=MSTX+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=MSTX+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=MSTX
Balance Sheet: http://finance.yahoo.com/q/bs?s=MSTX
Cash Flow: http://finance.yahoo.com/q/cf?s=MSTX+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/MSTX
Bloomberg: http://www.bloomberg.com/quote/MSTX:US
Morningstar: http://quotes.morningstar.com/stock/s?t=MSTX
Bussinessweek: http://investing.businessweek.com/research/st...icker=MSTX
Barchart: http://www.barchart.com/quotes/stocks/MSTX
OTC Short Report: http://otcshortreport.com/index.php?index=MSTX
Investopedia: http://www.investopedia.com/markets/stocks/MSTX/?wa=0
http://www.pennystocktweets.com/stocks/profile/MSTX
##### last known share structure ~ source: otcmarkets.com
Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: No Par Value
##### business description ~ source: otcmarkets.com
DD Notes ~ http://www.ddnotesmaker.com/MSTX
